WHO ICTRP trial
A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or…
CTIS2023-507276-53-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2023-507276-53-00 |
|---|---|
| Public title | A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE) |
| Scientific title | A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE) - M16-109 |
| Primary sponsor | AbbVie Deutschland GmbH & Co. KG |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;Canada;Korea, Republic of;Serbia;Taiwan;Japan;Australia;United Kingdom;Puerto Rico;Croatia;Greece;Italy;Spain |
| Conditions | Myelofibrosis MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Navitoclax, Product Code:PRD2202726, Pharmaceutical Form: TABLET, Other descriptive name: , Strength: , Product Name: Navitoclax, Product Code:PRD10634672, Pharmaceutical Form: TABLET, Other descriptive name: , Strength… |
| Registration date | Nov 3, 2024 |
| Target size | 191 |
| Secondary IDs | NCT03222609;2017-001398-17 |
| Registry page | euclinicaltrials.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: